Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

9.355 -0.005 (-0.05%)
Streaming Delayed Price Updated: 1:20 PM EDT, Aug 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 Next >
1 Cash-Producing Stock for Long-Term Investors and 2 We Turn Down
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
Topics Bonds
Avantor, Viatris, and Amneal Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Artificial Intelligence Economy
AMRX Q2 Deep Dive: New Product Launches and Specialty Momentum Shape Guidance
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) missed Wall Street’s revenue expectations in Q2 CY2025 as sales rose 3.2% year on year to $724.5 million. On the other hand, the company’s... 
Via StockStory
Earnings Scheduled For August 5, 2025
 
Via Benzinga
A Peek at Amneal Pharmaceuticals's Future Earnings
 
Via Benzinga
Revvity, Avantor, Azenta, Bio-Techne, and Amneal Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed... 
Via StockStory
Topics Bonds Economy Stocks
1 Value Stock to Keep an Eye On and 2 Facing Challenges
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
Amneal (AMRX) Q2 EPS Jumps 56%
Via The Motley Fool
Topics Economy
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Reports Mixed Q2 2025 Results: Earnings Beat, Revenue Miss
Amneal Pharmaceuticals (AMRX) reported mixed Q2 2025 results, with EPS beating estimates but revenue missing. Shares dipped slightly as investors weighed strong profitability against softer sales.... 
Via Chartmill
Topics Earnings
Amneal (NASDAQ:AMRX) Misses Q2 Sales Targets
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) fell short of the market’s revenue expectations in Q2 CY2025 as sales rose 3.2% year on year to $724.5 million. On the other hand, the... 
Via StockStory
Amneal Earnings: What To Look For From AMRX
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting earnings this Tuesday before the bell. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence Government World Trade
Q1 Earnings Highs And Lows: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AMRX) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
3 Profitable Stocks with Warning Signs
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
1 Small-Cap Stock to Consider Right Now and 2 to Keep Off Your Radar
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
Topics Supply Chain
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?
Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook. 
Via Benzinga
3 of Wall Street’s Favorite Stocks in the Doghouse
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
Topics Intellectual Property
Amneal Recalls Three Lots Of UTI Drug Over Concerns of Microbial Contamination: Retail Sticks To Bearish Territory
The observance of black spots was reported in a product quality complaint, the U.S. FDA said, while noting that oral products contaminated with Aspergillus may result in serious and life-threatening... 
Via Stocktwits
Topics Artificial Intelligence Product Recall
AMRX Q1 Earnings Call: Miss on Revenue, Margin Expansion, and Product Pipeline Progress
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 5.5% year on year to $695.4 million. On the other hand, the... 
Via StockStory
Topics Supply Chain
Amneal Gets FDA Nod For Self-Administrable Migraine Injection
The company said the injection is the first and only dihydroergotamine (DHE) autoinjector for treating migraine and cluster headaches. 
Via Stocktwits
Topics Data Breach
3 Russell 2000 Stocks in Hot Water
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher... 
Via StockStory
3 Value Stocks in Hot Water
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
Topics Supply Chain
3 Small-Cap Stocks Facing Headwinds
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson's Drug But Q1 Earnings Are Mixed
Amneal Pharmaceuticals reported first-quarter 2025 adjusted earnings per share of 21 cents, up from 14 cents a year ago. 
Via Benzinga
Amneal (NASDAQ:AMRX) Misses Q1 Sales Targets, Stock Drops 11.3%
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 5.5% year on year to $695.4 million. On the other hand, the company’s... 
Via StockStory
Earnings Scheduled For May 2, 2025
 
Via Benzinga
Examining the Future: Amneal Pharmaceuticals's Earnings Outlook
 
Via Benzinga
Amneal (AMRX) To Report Earnings Tomorrow: Here Is What To Expect
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting earnings tomorrow before market hours. Here’s what investors should know. 
Via StockStory
3 Profitable Stocks Skating on Thin Ice
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest
Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
2 Reasons to Avoid AMRX and 1 Stock to Buy Instead
Over the past six months, Amneal’s shares (currently trading at $6.85) have posted a disappointing 17.6% loss while the S&P 500 was down 8.1%. This might have investors contemplating their next move. 
Via StockStory
Topics Economy Government Stocks
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.